Candel Therapeutics (CADL) vs Tectonic Therapeutic (TECX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Tectonic Therapeutic (TECX) over the past year, gaining 10.8% versus a gain of 8.1%. Over five years, CADL leads with a -48.5% price change compared with -57.7% for TECX. Tectonic Therapeutic is the larger company by market cap ($405.3 million vs $395.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | TECX |
|---|---|---|
| Share price | $5.04 | $20.73 |
| Market cap | $395.37M | $405.26M |
| 1-day change | -1.75% | -1.47% |
| YTD return | -10.80% | -0.62% |
| 1-year return | +10.77% | +8.08% |
| 5-year return | -48.47% | -57.66% |
| EPS (TTM) | $-1.53 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-38.18M | $-74.15M |
| 52-week high | $14.00 | $39.53 |
| 52-week low | $4.35 | $16.77 |
| Distance from 52-week high | -64.00% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.60% | +242.50% |
| Average volume | 1.26M | 212.16K |
| Shares outstanding | 78.45M | 19.55M |
| Employees | 55 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Tectonic Therapeutic
TECX stock →Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
CADL vs TECX FAQ
Which is bigger, Candel Therapeutics or Tectonic Therapeutic?
Tectonic Therapeutic (TECX) is larger, with a market capitalization of $405.26M compared with $395.37M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or TECX?
CADL returned +10.77% over the past 12 months, compared with +8.08% for TECX (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Tectonic Therapeutic in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.